Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Mai 2025 04:00 ET | Quelle: AKAMPION

Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate

ODD granted for the treatment of soft tissue sarcomas (STS)Thermosome adds 4 patents to its growing patent estate Munich, Germany – May 12, 2025 – Thermosome, a drug development company focused on...
04. Dezember 2024 04:00 ET | Quelle: AKAMPION

Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001

Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to ﬁnal dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...
06. Februar 2024 04:00 ET | Quelle: AKAMPION

Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001

- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...